BCL6公司
淋巴瘤
疾病
医学
肿瘤科
阶段(地层学)
耐火材料(行星科学)
侵袭性淋巴瘤
内科学
B细胞
免疫学
生物
美罗华
抗体
古生物学
生发中心
天体生物学
作者
Lauren M. Stanoszek,Lauren B. Smith,Karen Grajewski,John Reneau,Ryan A. Wilcox,Anamarija M. Perry
标识
DOI:10.1016/j.clml.2020.09.006
摘要
High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (double-hit or triple-hit lymphoma) was introduced in the 2016 revision of the World Health Organization classification of lymphomas as a separate entity.1 These mature B-cell lymphomas are considered highly aggressive, with most patients presenting with advanced clinical stage disease (III/IV). Primary refractory disease following immunochemotherapy is common.2 Most patients are elderly, with a median age at diagnosis in the sixth to seventh decade, with only occasional reports of cases in young individuals.
科研通智能强力驱动
Strongly Powered by AbleSci AI